Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROSTVAC + Sm-153 in mCRPC
NCT00450619Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2007
- Primary completion
- Nov 2012
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rilimogene galvacirepvec in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Number of Patients With Stable Disease at 4.7 months and Progression Free Survival at 4 months. Started Feb 2007; status: completed.
02
Drugs
rilimogene galvacirepvec
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT00450619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00450619.